Immunome (IMNM) Guggenheim Securities Inaugural Healthcare Innovation Conference summary

Vision and strategy

• Focus on improving outcomes for cancer patients using antibody-drug conjugates (ADCs) and opportunistically adding targeted therapies when impactful.

• Emphasis on not being limited to one modality, drawing on experience building a leading ADC company previously.

AL102 acquisition and development

• Licensed AL102, a gamma-secretase inhibitor, due to its strong chemistry, underutilized potential, and best-in-class profile.

• Phase II data showed consistent efficacy across multiple dosing schedules, with response rates in the mid-60s and deep tumor regression.

• Phase III trial for AL102 in desmoid tumors is fully enrolled, with unblinding expected in the second half of 2025.

• Plans to commercialize AL102 globally, leveraging a new head of commercial with extensive launch experience.

Market opportunity and commercialization

• Desmoid tumor prevalence in the US is over 30,000, with 6,000–7,000 treated annually and 1,600 new cases per year; similar numbers in Europe.

• Once-daily dosing and superior efficacy could drive adoption, especially for new or non-responsive patients.

• Global clinical trial footprint includes US, Europe, Israel, and Australia, supporting worldwide commercialization plans.

• Strategy includes direct launches in major markets and distributor partnerships in select territories.